Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of parental and wild-type SK-N-Be(2)C neuroblastoma cell lines as well as those co-treated with the histone deacetylase inhibitor SAHA

ABSTRACT: Analysis of varied biologic pathways in neuroblastoma SK-N-Be(2)C cells grown in doxorubicin and/or SAHA. We hypothesized that SK-N-Be(2)C cells undergo a mesenchymal change through mesenchymal change resulting in a more invasive as well as drug resistant phenotype, and that the mechanism of SAHAs effect on drug resistance may be revealed through this analysis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE47669 | GEO | 2016/05/31

SECONDARY ACCESSION(S): PRJNA207086

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide analysis of parental and wild-type SK-N-Be(2)C neuroblastoma cell lines as well as those co-treated with the histone deacetylase inhibitor SAHA

Project description:Analysis of varied biologic pathways in neuroblastoma SK-N-Be(2)C cells grown in doxorubicin and/or SAHA. We hypothesized that SK-N-Be(2)C cells undergo a mesenchymal change through mesenchymal change resulting in a more invasive as well as drug resistant phenotype, and that the mechanism of SAHAs effect on drug resistance may be revealed through this analysis. Total RNA was isolated from wild type, SAHA treated wild type cells, doxorubicin resistant, and SAHA treated doxorubicin resistant SK-N-Be(2)C cell lines in triplicate.

2016-05-31 | E-GEOD-47669 | biostudies-arrayexpress

Genome-wide analysis of parental wild-type and derived doxorubicin resistant SK-N-SH neuroblastoma cell lines as well as those co-treated with the histone deacetylase inhibitor SAHA

Project description:Analysis of varied biologic pathways in neuroblastoma SK-N-SH cells grown in doxorubicin and/or SAHA. The hypothesis was that SK-N-SH cells undergo a mesenchymal change through mesenchymal change resulting in a more invasive as well as drug resistant phenotype, and that the mechanism of SAHAs effect on drug resistance may be revealed through this analysis. Total RNA was isolated from wild type, SAHA treated wild type cells, doxorubicin resistant, and SAHA treated doxorubicin resistant SK-N-SH cell lines in triplicate.

2016-05-31 | E-GEOD-47668 | biostudies-arrayexpress

Genome-wide analysis of parental wild-type and derived doxorubicin resistant SK-N-SH neuroblastoma cell lines as well as those co-treated with the histone deacetylase inhibitor SAHA

2016-05-31 | GSE47668 | GEO

Expression data in MDA-MB-231 breast cancer cell lines with Histone deacetylase SAHA treatment

Project description:Analysis of gene expression change after 8hr's treatment with 5μM SAHA, which is a histone deacetylase inhibitor, in MDA-MB-231 cell lines.

2016-01-26 | GSE77200 | GEO

Examination of gene expression in human breast cancer cells exposed to the HDAC inhibitor SAHA

Project description:The identification of proteins that change in response to a drug perturbation can shed light on the molecular mechanisms of the drug and its potential use in therapies. Histone deacetylases (HDACs) are targets for cancer therapy. Suberoylanilide hydroxamic acid (SAHA) is an FDA approved HDAC inhibitor used for the treatment of cutaneous T-cell lymphoma. ING2 is a non-catalytic component of the Sin3/HDAC complex. To obtain a better mechanistic understanding of the Sin3/HDAC complex in cancer, we extended its protein-protein interaction network and identified a mutually exclusive pair within the complex. We then assessed the effects of SAHA on the disruption of the complex network through six homologous baits. SAHA perturbs multiple protein interactions and therefore compromises the composition of large parts of the Sin3/HDAC network. A comparison of the effect of SAHA treatment on gene expression in breast cancer cells to a knockdown of the ING2 subunit indicated that a portion of the anticancer effects of SAHA may be attributed to the disruption of ING2's association with the complex. Cells from human breast cancer cell line MDA-MB-231 were treated with the HDAC inhibitor drug SAHA in duplicate and compared to a DMSO vehicle control in triplicate, for a total of 5 samples.

2014-09-01 | E-GEOD-60124 | biostudies-arrayexpress

Global mRNA expression profiling of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy

Project description:Global mRNA expression profiles of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy were collected using Affymetix mouse whole genome array (Mouse Genome 430A 2.0 Array) . Primary PDAC cells isolated from Ptf1aCre/+;Kras+/LSL-G12D;p53lox/lox (Kras;p53) mice were treated either with JQ1 (100 nM) or SAHA (2000 nM) or vehicle 10% (2-Hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich) or as combination therapy with the indicated dosage for monotherapy. Total RNA isolation was performed after 6 hours of treatment.

2015-09-20 | GSE64836 | GEO

Global mRNA expression profiling of murine primary PDAC cells following JQ1 or SAHA monotherapy as well as JQ1-SAHA combination therapy

2015-09-20 | E-GEOD-64836 | biostudies-arrayexpress

Examination of gene expression in human breast cancer cells exposed to the HDAC inhibitor SAHA

2014-09-01 | GSE60124 | GEO

The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) alleviates salinity stress in cassava (Manihot esculenta Crantz)

Project description:To elucidate the molecular mechanism involved in increased tolerance to high-salinity stress by the application of HDAC inhibitor named SAHA

2016-12-01 | GSE84715 | GEO

Dissection of anti-tumor activity of histone deacetylase inhibitor SAHA in NPC cells via quantitative phosphoproteomics

Project description:Suberoylanilide hydroxamic acid (SAHA), as a pan HDAC inhibitor, has been approved for clinical use and it has been demonstrated to treat solid tumor. Nevertheless, the mechanism underlying the therapeutic effects of SAHA on tumors are still not fully understood. Protein phosphorylation is one of the most important regulatory events in cells, regulating primary biological processes, such as cell division, growth, migration, differentiation, and intercellular communication. The impact of SAHA treatment on cellular phosphorylation and signaling pathways might contribute to our understanding on its therapeutic mechanism. For this purpose, by combining tandem mass tags(TMT)-based quantitative proteomics and titanium dioxide-based phosphopeptide enrichment, we for the first time comprehensively identified and quantified protein phosphorylation in NPC cells toward SAHA treatment. we identified 7430 phosphorylation sites on 2456 phosphoproteins in the NPC cell line 5-8F, of which 1176 phosphorylation sites on 528 phosphoproteins were significantly expressed upon SAHA treatment. Biological analysis show that SAHA can influence several biological processes including mRNA/DNA processing, cell cycle. Furthermore, signaling pathway analysis demonstrate that SAHA can activate cell cycle regulation related pathway such as p53 signalling pathway, and inactivate energetic pathway such as AMPK pathway etc. Overall, our study presents evidence at a phosphoproteomic level that SAHA can inhibit NPC cell growth by regulating the cell cycle and cell energy metabolism. Our findings will contribute to elucidation of the mechanisms through which SAHA exerts its anticancer effects.

2020-08-20 | PXD021029 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data